Abstract Background: The role of human epidermal growth factor receptor (HER) 3 and HER4 has been elucidated in gastric cancer. HER1 and HER2 overexpression are regarded as prognostic factors and targets of treatment. The dimerization of the HER family receptors activates downstream signal pathways and promotes tumor progression. This study investigated the positive correlation between HER1and HER4 expression and the prognosis of patients with gastric cancers. Experimental Design: Tumor samples were obtained from gastric adenocarcinomas of 134 patients who underwent a gastrectomy from 1999 to 2002. The expression of each HER was analyzed in the tumor by immunohistochemical staining. Parametric correlations were done between HER expression and the clinicopathologic findings. A multivariate analysis was done with the overall survival. Results: HER3 expression was significantly associated with parameters involved with tumor progression, including the depth of tumor invasion (T 1 versusT 2 -T 4 ; P = 0.000), involved lymph nodes (P = 0.000), distant metastasis (P = 0.008), tumor stage (P = 0.000), and recurrent disease (P = 0.000). HER1was also significantly associated with those factors excluding distant metastasis. A significant relationship was observed between the expression of HER1 and HER3 (P = 0.000). HER3 overexpression was associated with a significantly worse survival (P = 0.0000) and was an independent prognostic factor in the multivariate analysis (hazard ratio, 2.382; 95% confidence interval, 1.009-5.625; P = 0.048). Conclusions: HER3 overexpression is strongly associated with tumor progression and poor prognosis of patients with gastric cancer. It may become a new prognostic factor and a target of treatment.
Gastric cancer is one of the leading causes of cancer-related death worldwide (1) . A poor outcome is observed in patients with advanced gastric cancer. Most patients experience recurrent disease, even after a radical resection. Adjuvant systemic therapies have been developed to improve this poor perspective (2) . The survival time of patients with unresectable gastric cancers has been prolonged by the introduction of new regimens including taxans, irinotecan, and novel fluoropyrimidines (3, 4) . However, the median survival time is no >13 months even in patients receiving those chemotherapies (4) . New biological agents, such as tyrosine kinase inhibitors of epidermal growth factor receptor, have been evaluated in gastrointestinal cancers.
The family of type I human epidermal growth factor receptors (HER) consists of four homologue members: HER1/ erbB1, HER2/erbB2, HER3/erbB3, and HER4/erbB4. All share a common structure, with an extracellular ligand-binding domain, a transmembrane domain, and an intracytoplasmic tyrosine kinase domain (5 -7) . Ligand binding to these receptors induces the formation of receptor homodimers and heterodimers and the activation of downstream signaling pathways. Therefore, the HER family could contribute to malignant progression. HER1 and HER2 overexpression in gastric cancers are thought to be prognostic factors and targets of novel biological agents (8 -18) . Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, did not provide benefit as a single agent for patients with gastric cancer (19) . Another tyrosine kinase inhibitor, erlotinib, was also ineffective for gastric cancer (20) . Cetuximab, an antiepidermal growth factor receptor monoclonal antibody approved for treatment of advanced colorectal cancer, is attempted for gastric cancer. Trastuzumab, a monoclonal antibody against the p185 HER2 protein, had therapeutic efficacy in breast cancer with HER2 overexpression (21, 22) . A phase III trial of combined chemotherapy with trastuzumab for unresectable advanced gastric cancers with HER2 overexpression is ongoing. Although the effect of HER3 or HER4 expression in gastric carcinoma has not been sufficiently, HER3 expression is observed frequently in advanced gastric cancers (23, 24) . Kataoka et al. reported HER4 gene expression to be higher in gastric cancerous tissue in comparison with the adjacent gastric mucosa (25) . HER1 to HER4 expression was investigated in both early and advanced gastric cancers to elucidate the clinical effect of the HER family on gastric cancer.
Patients and Methods
Patients. The present study included a total of 134 patients with primary gastric adenocarcinomas who underwent a surgical procedure from January 1999 to December 2002 at the Department of Esophagogastric Surgery, Tokyo Medical and Dental University (Table 1) . Each tumor was classified according to the tumor-nodemetastasis (TNM) classification advocated by International Union against Cancer. A curative gastrectomy (R 0 ) was done for 120 (90%) patients without adjuvant chemotherapy. Eight of 14 patients in stage IV with a noncurative resection (R 1 and R 2 ) received postoperative chemotherapy. All patients were evaluated for recurrent disease by an examination of tumor markers or diagnostic imaging (computed tomography, ultrasonography, magnetic resonance imaging, and endoscopy) every 3 to 6 mo. Forty-one patients (31%) died from recurrent or metastatic disease. The median follow-up time was 1,943 d in the present study (range, 50-3,197 d) .
Immunostaining of HER1 to HER4. The following antibodies were used for immunohistochemistry: HER1 (mouse monoclonal antibody; Novocastra Laboratories), HER2 (mouse monoclonal antibody; Nichirei), HER3 (mouse monoclonal antibody; Neomarkers), and HER4 (rabbit polyclonal antibody; Neomarkers). All the available H&E-stained slides of the surgical specimens were reviewed, and representative paraffin blocks for each case were selected for the immunohistochemical study. Following deparaffinization in xylene, the slides were rehydrated and washed with double-distilled water. For HER1 and HER4 staining, antigen retrieval by microwave pretreatment was carried out for 10 min in 0.01 mol/L citrate buffer (pH 6) at 800 W. For HER2 staining, the sections were treated with 50 mmol/L Tris-HCl (pH 7.6) containing 0.1% type-XXIV protease (SIGMA-ALDRICH). The endogenous peroxidase activity was quenched by a 15-min incubation in a mixture of 3% hydrogen peroxide solution in 100% methanol. After washing with PBS, the specimen was incubated with the primary antibody to each HER protein, respectively, using the following procedure: HER1 antibody (dilution 1:50) and HER2 antibody (1:50) for 1 h at room temperature, and HER3 antibody (1:35) and HER4 antibody (1:100) overnight at 4jC. Sections were washed with 0.1% Tween 20/PBS thrice. For HER1, HER2, and HER4 staining, sections were incubated with peroxidase-labeled antirabbit or antimouse antibody (Histofine Simplestain Max PO; Nichirei) for 30 min at room temperature. The SAB-PO kit (Nichirei, Japan) was used for HER3 staining by the conventional streptavidin-biotin method. Peroxidase activity was detected with diaminobenzidine (DAB; Nichirei). The sections were counterstained with hematoxylin.
HER receptor expression was graded by two independent observers using a 4-point scale, where 0 = no staining, 1+ = light staining, 2+ = moderate staining, and 3+ = strong staining. According to the criteria of HER1 and HER2 membranous staining, which have been widely accepted (26 -28) , the intensity of membranous staining was carefully determined. In addition, the intensity of cytoplasmic staining was also determined. Slices with a score of 2+ or 3+ were classified as having either a ''high expression'' or an ''overexpression,'' in contrast to slices with 0 or 1+, which were classified as having a ''low expression.'' Finally, tumors with high expression in either the membrane or cytoplasm were classified as the high expression group.
Statistical analysis. The m 2 test was used to test the possible association between the expression of each HER receptor and the clinicopathologic parameters. It was also used to assess the correlation between HER expression. The Mann-Whitney U test was applied for analysis of the relationship between HER expression and the patient's age. Kaplan-Meier curves were plotted to assess the effect of HER expression on overall survival. Different survival curves were compared using the log-rank test. The multivariate proportional Cox models were applied to assess the prognostic significance of each HER expression, tumor stage, and age. A P value of =0.05 was considered significant. 
Translational Relevance
Some inhibitors of human epidermal growth receptor 1 (HER1) and HER2 have been used for the treatment of breast, colon, and lung cancers, and those efficacies have been elucidated. However, the efficacy of such inhibitors for gastric cancer has not yet been reported. HER3 is associated with the signals mediated from HER1or HER2, and it may be also associated with resistance to anti-HER1 or anti-HER2 therapies. The relevance of HER3 overexpression with timorous progression has been reported in various cancers. We herein showed HER3 overexpression to be significantly associated with the progression and prognosis in gastric cancer, whereas HER1or HER2 overexpression did not show any such association. In in vitro studies, the blocking of HER3 decreased downstream signals and also caused the death of tumor cells. HER3 may therefore become a potentially useful target of clinical treatment, especially for gastric cancer. 
Results
HER family immunostaining. Overexpression (moderate or strong positivity) of HER1 was found in 40 (30%) of all tumors, HER2 in 24 (18%), HER3 in 79 (59%), and HER4 in 116 (86%). Overexpressions of HER1 and HER2 were only observed in the membrane. HER3 membranous and cytoplasmic overexpression were found in 18 (13%) and 78 (58%) samples, respectively. Seventeen of these samples showed overexpression in both sites (12%). HER4 overexpression was observed in 30 tumors (22%) in the membrane, 103 (84%) in the cytoplasm, and 28 (21%) in both sites (Fig. 1) .
Clinicopathologic parameters and HER expression. HER3 overexpression was significantly associated with the depth of tumor invasion (T 1 versus T 2 -T 4 ; P = 0.000), involved lymph nodes (P = 0.000), distant metastasis (P = 0.008), tumor stage (P = 0.000), and recurrent disease (P = 0.000). HER1 was also significantly associated with the depth of tumor invasion (P = 0.000), involved lymph nodes (P = 0.004), tumor stage (P = 0.001), recurrent disease (P = 0.03), but not with distant metastasis (P = 0.777). The expression of HER2 was more frequently observed in the intestinal type than in the diffuse type (P = 0.007), whereas no correlation with any other clinicopathologic parameters was noted. HER4 expression was not significantly associated with any parameters (Table 2) .
A significant relationship was observed between the membranous expression of HER1 and HER3, HER1 and HER4, and HER3 and HER4 (P = 0.000, 0.001, and 0.000, respectively). HER1 membranous expression and either HER3 or HER4 cytoplasmic expression also showed a significant correlation (P = 0.000 and 0.036, respectively), whereas HER3 and HER4 cytoplasmic expression was not significantly associated (Table 3) .
No HER expression was significantly associated with age and sex, although HER3 overexpression tended to be correlated with old age and women.
Prognostic significance and HER expression. The patients with HER3 overexpressing tumors had significantly poor survival (P = 0.0000), whereas HER1 overexpression tended to correlate with poor prognosis, but not significantly (P = 0.0753). HER2 and HER4 expression was not significantly Fig. 2 ). In addition, the co-overexpression of HER3 and HER1, or HER1 and HER4, was significantly associated with a poor prognosis (P = 0.0124 and 0.0001, respectively). The co-overexpression of the three HERs was also significantly associated with a poor prognosis (P = 0.0258). The prognostic relevance of each HER was assessed using a multivariate proportional hazard model adjusted for the established clinical prognostic factors: International Union against Cancer stage, histologic type, and age (Table 4) . Although the International Union against Cancer stage was the most dominant prognostic factor (hazard ratio, 5.841; 95% confidence interval, 2.495-13.676; P = 0.000), HER3 expression was also an independent prognostic factor (hazard ratio, 2.382; 95% confidence interval, 1.009-5.625; P = 0.048).
Discussion
The result of this study suggests that HER3 overexpression predicts poor survival for patients with gastric cancers. The prognostic relevance of HER3 expression remains to be elucidated in gastric cancer. Sanidas et al. reported that positive HER3 staining was found in 91 advanced gastric tumors with higher intensity than that in the adjacent mucosa (23) . They proposed that HER3 expression might affect tumor progression. They detected no correlation between HER3 overexpression and (24) . The current study also showed a lower frequency of HER3 overexpression in early gastric cancer in comparison with advanced disease. Tanner pointed out that HER3 expression is an independent predictor of poor prognosis in ovarian cancer (29) . Several investigators showed significant correlation between HER3 overexpression and decreased survival of patients with colorectal (30) and breast cancer (26, 27) HER3 overexpression is significantly associated with poor prognostic factors in breast cancer (31 -35) . In squamous cell carcinoma, including laryngeal cancer (36) and esophageal cancer (37), HER3 overexpression is significantly associated with involved lymph nodes. The current findings are consistent with those reports, although conflicting outcomes have been also reported. HER3 expression was not significantly associated with the survival of patients with breast cancer (33, 38 -40) , and it was correlated with prolonged 10-year survival (41) . In colorectal cancer, Kountourakis et al. found no significant relationship between HER3 expression and any parameters involved with tumor progression (42) , and Lee reported a relationship with patients in the early stage of the disease (43) . The frequency of HER3 overexpression is low in advanced ovarian cancer (44) . These discrepancies may be partially explained by the different methods used for determination of HER3 status, or by different coexpression of HER3 and another HER. The tyrosine kinase domain of HER3 is nonfunctioning, and the dimerization of HER3 with another HER is required for activating signal pathways. HER2 is regarded as the preferred partner (45) , and requires HER3 to promote cell proliferation in breast cancer (46) . Co-overexpression of HER3 and HER2 is associated with significantly decreased survival in breast cancer, but individual overexpression is not (33, 38) . An increased HER3 level is related to a concomitant increase in the HER2 level in colorectal cancer (47) . The present study, however, showed no significant correlation between the membranous expression of HER3 and HER2. Co-overexpression of HER3 and HER2 was not associated with prognosis (data was not shown).
HER2 was regarded as a prognostic factor for patients with gastric cancer (12 -18) , although several reports have revealed no significant relationship between HER2 overexpression or amplification and poor prognosis in gastric cancer (48 -52) . Garcia et al. assumed that discrepancies with the determination of the HER2 status and its clinical significance were due to problems of selecting the best methodology (18) . In the present study, HER2 expression was not significantly associated with any tumor-progressive parameters. HER2 expression was more frequently observed in the intestinal type than in the diffuse type, and similar results have been reported by other investigators (16, 49) . Differences in the frequencies with HER2 expression in gastric cancer may be partly explained by differences in the histologic types.
HER3/HER1 heterodimer formation was also confirmed in gastric cancer cells (53) , and a significant correlation was observed between HER3 and HER1 expression. HER1 overexpression has been regarded as a poor prognostic factor for patients with gastric cancer (8 -11, 54) . HER1 expression was not an independent predictive factor in the present study, although it tended to correlate with survival in the KaplanMeier model. HER3 expression was correlated more strongly with distant metastasis and survival of patients with gastric cancer than HER1 expression.
The effect of HER4 expression in gastric cancer has not been elucidated. HER4 overexpression in breast cancer is associated with significant better survival in some studies (26, 38, 40) , and conversely, with worse survival in others (31, 39) . HER4 expression was not associated with the prognosis of patients with colorectal cancer, although its membranous expression was associated with involved lymph nodes (42) . HER2 and HER4 co-overexpression correlated significantly with poor prognosis in colorectal cancers (43) . In the present study, HER4 overexpression was found frequently in both early and advanced gastric cancer without a prognostic relevance.
Membranous expression of HER1 and HER2 is regarded as an important parameter, although HER3 and HER4 staining was observed predominantly in the cytoplasm of cancer cells. This staining pattern coincides with other reports on colorectal (30, 42) , ovarian (29) , head or neck (55) , and breast cancers (38) . HER3 cytoplasmic expression may be important to the prognosis of patients with gastric cancer, although an assessment using HER3 staining is not still standardized like that for HER1 and HER2. HER3 had not been regarded as a treatment target in the view of the inactive tyrosine kinase function. However, an antibody directed against HER3 inhibited HER3-mediated signaling pathways in breast cancer cells even in cancer cells resistant to HER2 (56) . A recent study of gastric cancer cells showed that HER family kinases were targets of amplified fibroblast growth factor receptor 2, and inhibition of HER3 resulted in a loss of cell proliferation introduced by fibroblast growth factor receptor 2 (57) . Therefore, HER3 blocking therapies may be a new strategy for gastric cancer as well as anti-HER1 or anti-HER2 treatment.
In conclusion, HER3 or HER1 overexpression was relevant with tumor progression. Especially, HER3 overexpression was significantly associated with poor prognosis, and it may become a new prognostic factor and a target of treatment.
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